Iovance Biotherapeutics, Inc. | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company based in San Carlos, California. Founded in 2007, the company specializes in the development of tumor infiltrating lymphocyte (TIL) therapies designed to harness the immune system against solid tumor cancers, with particular focus on metastatic melanoma. Its approach aims to establish TIL therapies as a global standard of care by emphasizing innovation and a patient-centric focus.

The core platform utilizes autologous TIL therapy, extracting TIL cells from a patient’s tumor, expanding them in a laboratory environment, and reinfusing the cells to target cancer neoantigens. Approved products include Amtagvi (lifileucel) for unresectable or metastatic melanoma and Proleukin for metastatic melanoma and renal cell carcinoma. The company is advancing additional candidates in its pipeline for cancers such as cervical and non-small cell lung cancer, operates a GMP manufacturing facility in Philadelphia, and partners with leading institutions for clinical research.